Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma

British Journal of Haematology

Volumn 159, Issue 2, 2012, Pages 252-255

  Ferreri, Andrés J M ^a   Bruno Ventre, Marta ^a   Donadoni, Giovanni ^a   Cattaneo, Chiara ^b   Fumagalli, Luca ^c   Foppoli, Marco ^a   Mappa, Silvia ^a   Govi, Silvia ^a   Nicola, Massimo di ^d   Rossi, Giuseppe ^b   Tirelli, Umberto ^e   Caligaris Cappio, Federico ^a   Spina, Michele ^e   Re, Alessandro ^b  

^a Unit of Lymphoid Malignancies   (Italy)

^b Spedali Civili di Brescia   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Acquired immunodeficiency syndrome; Autologous transplant; Burkitt lymphoma; Human immunodeficiency virus; Non Hodgkin lymphoma

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; MELPHALAN; METHOTREXATE; RITUXIMAB; STEROID; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SHORT COURSE THERAPY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; CARMUSTINE; CYTARABINE; FEMALE; HIV SEROPOSITIVITY; HUMANS; MALE; MELPHALAN; MIDDLE AGED; PODOPHYLLOTOXIN; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 84866860418     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12020     Document Type: Letter

References (10)

1. Barnes, J.A., Lacasce, A.S., Feng, Y., Toomey, C.E., Neuberg, D., Michaelson, J.S., Hochberg, E.P. & Abramson, J.S. (2011) Evaluation of the addition of rituximab to CODOX-M/IVAC for burkitt's lymphoma: a retrospective analysis. Annals of Oncology, 22, 1859-1864.
2. Cortes, J., Thomas, D., Rios, A., Koller, C., O'Brien, S., Jeha, S., Faderl, S. & Kantarjian, H. (2002) Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer, 94, 1492-1499.
3. Dunleavy, K., Little, R.F., Pittaluga, S., Grant, N., Wayne, A.S., Carrasquillo, J.A., Steinberg, S.M., Yarchoan, R., Jaffe, E.S. & Wilson, W.H. (2010) The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood, 115, 3017-3024.
4. Galicier, L., Fieschi, C., Borie, R., Meignin, V., Daniel, M.T., Gerard, L. & Oksenhendler, E. (2007) Intensive chemotherapy regimen (LMB86) for st jude stage IV AIDS-related burkitt lymphoma/leukemia: a prospective study. Blood, 110, 2846-2854.
5. Lim, S.T., Karim, R., Nathwani, B.N., Tulpule, A., Espina, B. & Levine, A.M. (2005) AIDS-related burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. Journal of Clinical Oncology, 23, 4430-4438.
6. Montoto, S., Wilson, J., Shaw, K., Heath, M., Wilson, A., McNamara, C., Orkin, C., Nelson, M., Johnson, M., Bower, M. & Cwynarski, K. (2010) Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated burkitt's lymphoma. AIDS (London, England), 24, 851-856.
7. Di Nicola, M., Carlo-Stella, C., Mariotti, J., Devizzi, L., Massimino, M., Cabras, A., Magni, M., Matteucci, P., Guidetti, A., Gandola, L. & Gianni, A.M. (2004) High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for burkitt's lymphoma in adults. British Journal of Haematology, 126, 815-820.
8. Oriol, A., Ribera, J.M., Bergua, J., Gimenez Mesa, E., Grande, C., Esteve, J., Brunet, S., Moreno, M.J., Escoda, L., Hernandez-Rivas, J.M. & Hoelzer, D. (2008) High-dose chemotherapy and immunotherapy in adult burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer, 113, 117-125.
9. Rodrigo, J.A., Hicks, L.K., Cheung, M.C., Song, K.W., Ezzat, H., Leger, C.S., Boro, J., Montaner, J.S., Harris, M. & Leitch, H.A. (2012) HIV-associated burkitt lymphoma: good efficacy and tolerance of intensive chemotherapy including CODOX-M/IVAC with or without rituximab in the HAART era. Advances in Hematology, 2012, 735392.
10. Sparano, J.A., Lee, J.Y., Kaplan, L.D., Levine, A.M., Ramos, J.C., Ambinder, R.F., Wachsman, W., Aboulafia, D., Noy, A., Henry, D.H., Von Roenn, J., Dezube, B.J., Remick, S.C., Shah, M.H., Leichman, L., Ratner, L., Cesarman, E., Chadburn, A. & Mitsuyasu, R. & AIDS Malignancy Consortium. (2010) Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-hodgkin lymphoma. Blood, 115, 3008-3016.